AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00654511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, 2mcg/kg, Intravenous (IV)
Study NCT00075491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00075491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00075491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT00075491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00075491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02082158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Procedures
Description: Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
Study NCT02082158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Procedures
Description: Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
Study NCT01443416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
Study NCT01443416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal conjugate vaccine
Description: The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
Study NCT03126656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
Study NCT04126239 — intervention group
Intervention type: OTHER
Intervention: Online survey - questionnaire
Description: Online survey - questionnaire
Study NCT01129739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A (CsA)
Description: CsA 5mg/kg po for 6 months
Study NCT03670134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Nvision VLE Imaging System
Description: Volumetric laser Endomicroscopy (VLE) will be performed by using the Nvision VLE Imaging System (Nine Point Medical, MA) consists of an imaging console, monitor and optical probe. The optical probe is centered by a balloon (diameter: 14 mm, 17 mm, 20 mm; length: 6 cm) that is deployed through a diagnostic gastroscope's instrument channel. Imaging is performed by automatic helical pullback of the probe from the distal to the proximal end of the balloon over 90 seconds.
Study NCT02800031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Study NCT00240617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan succinate/naproxen sodium
Description: comparator
Study NCT00240617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match
Study NCT02182414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127 NA (TF-I)
Description: 200 mg tablet
Study NCT02182414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA (TF-II)
Description: 400 mg tablet
Study NCT02182414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA delayed release
Description: 400 mg tablet
Study NCT04736355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: oral, for 24 weeks
Study NCT02182414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (10% HPMC)
Description: 400 mg tablet
Study NCT02182414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (15% PEO)
Description: 400 mg tablet
Study NCT02182414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (20% HPMC)
Description: 400 mg tablet
Study NCT04038229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery pathway
Description: The applied protocol include psychological screening for yellow flags, preoperative gabapentin, peroperative multimodal preemptive management and postoperative holistic evaluation short -and long term
Study NCT02057692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001
Description: LUM001 administered orally
Study NCT00654511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, 4mcg/kg Intravenous (IV)
Study NCT03017924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q collar
Description: q-collar concussion prevention device
Study NCT03314519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography by experienced anaesthesiologist
Description: Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
Study NCT02057692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally
Study NCT06037824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: cryotherapy was added to rehabilitation\*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~\* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern.
Study NCT03314519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic bronchoscopy for double lumen tube's position
Description: Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
Study NCT01540916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase minute ventilation
Description: Respiratory rate will be increase in order to have a 30% increase of minute ventilation
Study NCT01540916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease minute ventilation
Description: Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
Study NCT06037824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy was added to rehabilitation\*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~\* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern.
Study NCT00590018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone taper (100mg/m2/day --> 25mg/m2/day) over 5 days intravenously.
Study NCT00590018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 5 days intravenously.
Study NCT03930212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: received rectal progesterone suppositories 400 mg once daily
Study NCT03930212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: received placebo suppositories rectally once daily.
Study NCT00344149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab (Mabthera)
Description: I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
Study NCT00344149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera)
Description: I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
Study NCT02473159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
Study NCT00941616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate®
Description: 80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
Study NCT00941616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate®
Description: Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
Study NCT01463904 — intervention group
Intervention type: PROCEDURE
Intervention: SADI-S 250
Description: Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
Study NCT04426825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
Study NCT04426825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT03584646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nokia GO Wearable StepTracker
Description: All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.
Study NCT01620632 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy assisted ERCP
Description: Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
Study NCT04137276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C, vitamin B1
Description: vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
Study NCT04137276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B1
Description: thiamine 200 mg/12 hours for 3 days
Study NCT04335266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: SHR2554
Study NCT00234858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trandolapril/verapamil
Description: 2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
Study NCT03207958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: -Given over 1 hour
Study NCT01529307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS266
Description: TAS266 IV infusions given weekly
Study NCT00641199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jarro-Dophilus EPS probiotics
Description: Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
Study NCT00641199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jarro-Dophilus EPS probiotics
Description: Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
Study NCT04377906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modification Lifesyle
Description: high protein-fiber and exercise
Study NCT02512055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
Study NCT06475625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study NCT06475625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro™ or Orsiro_Mission™ stent
Description: Percutaneous coronary intervention with Orsiro™ or Orsiro_Mission™ stents
Study NCT00784134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
Study NCT00784134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
Study NCT01901172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Description: Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
Study NCT01901172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Description: Daily for 5 days followed by 23 days rest per cycle
Study NCT01901172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Description: Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
Study NCT01901172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Description: Single doses Days 1 and 11
Study NCT01901172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: posaconazole
Description: Multiple doses Days 8-14
Study NCT04736355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, for 24 weeks
Study NCT03584646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reminder
Description: Medication reminders are sent to participants in Arm 2 on a daily basis.
Study NCT06015932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Participate in CBCSM group sessions
Study NCT06015932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT06015932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT03584646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly Check-in appointment with study team or provider
Description: Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
Study NCT04528576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dragonfly mitral valve repair system
Description: With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
Study NCT02241135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV7201 mRNA
Description: CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
Study NCT00618540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
Study NCT00618540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age \<12 months)
Study NCT00618540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age \<12 months)
Study NCT00618540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
Study NCT03125382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carelink System
Description: Patients start to perform device data transmission through Carelink system
Study NCT03125382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In office standard visit
Description: Patients start or maintain in office standard visits
Study NCT00130780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-surgical Treatment with Bevacizumab plus Chemotherapy
Description: On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
Study NCT00130780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
Description: Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
Study NCT03896841 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Ocular Findings Observations
Study NCT00355914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Facet Joint Nerve Block
Description: Lumbar Facet Joint Nerve Block
Study NCT00355914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Facet Joint Nerve Block
Description: Lumbar Facet Joint Nerve Block
Study NCT00633854 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound examination
Description: Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
Study NCT03457246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-Pigment rich texture
Study NCT03457246 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydrance optimale riche
Study NCT02692742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myelo001
Description: Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
Study NCT02692742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
Study NCT03812003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
Study NCT03368833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: 12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.
Study NCT04580303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: collagenase clostridium histolyticum
Description: Delivered via uniform grid injection techniques.
Study NCT00793286 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesh fixation by staples
Description: Mesh fixation by staples
Study NCT00793286 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesh fixation by glue
Description: Mesh fixation by glue
Study NCT01290224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scrambler therapy
Description: Undergo MC5-A therapy
Study NCT01290224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sham intervention
Description: Undergo sham procedure
Study NCT01290224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00521937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermagen®
Description: Weekly topical applications